罗氟司特片中国上市了吗？

The European Union approved the marketing of roflumilast film tablets in July 2010 for the treatment of chronic obstructive pulmonary disease (COPD). Roflumilast film tablet is a selective phosphodiesterase 4 (PDE4) inhibitor and is the first new class of chronic obstructive pulmonary disease (COPD) treatment drug approved by the EU in more than a decade. Roflumilast film tablet is a once-daily oral tablet that must be combined with other bronchodilators. Roflumilast is suitable for the maintenance treatment of severe chronic obstructive pulmonary disease COPD (post-diastolic FEV1 less than 50% of the expected value) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. Roflumilast film tablets, as a new type of drug for the treatment of chronic obstructive pulmonary disease COPD, are expected to be launched on the European market soon. The first countries to be launched will be Germany and the United Kingdom.

In vivo, roflumilast tablets have an effect on multiple aspects of the pathogenesis of chronic obstructive pulmonary disease (COPD), such as tobacco-induced pulmonary inflammatory response, respiratory ciliary dyskinesia, pulmonary fibrosis, emphysema, airway remodeling, oxidative stress response, pulmonary vascular remodeling and pulmonary hypertension, etc.

Have Roflumilast tablets been launched in China? Roflumilast tablets are not marketed in the country.

It is understood that the current cost-effective roflumilast film tablets are 500μg*90 tablets and sell for about $2,850 per box. The price is not fixed due to factors such as exchange rate fluctuations. If patients want to know the specific price information of this drug, or want to purchase cost-effective roflumilast overseas, they can consult with domestic reliable overseas medical service companies (such as Medical Companion Travel).

Four phase III clinical studies laid the foundation for the approval of this product. More than 3,000 patients with chronic obstructive pulmonary disease (COPD) were included in two pivotal placebo-controlled clinical studies. Studies have shown that roflumilast film tablets can significantly improve patients with moderate to severe exacerbations and prediastolic FEV1, regardless of whether it is combined with a long-acting β2 agonist. The study also demonstrated that roflumilast film tablets significantly improved patients' lung function compared with placebo.

The above is the introduction about roflumilast, I hope it can help everyone.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related hot articles